AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Article excerpt
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2026. "Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade," said Robert A. Bradway, chairman and chief executive officer. Key results include: References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q2 '26 Q2 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 510 $ 443 $ 953 $ 696 37 % EVENITY ® 550 164 714 518 38 % Prolia ® 478 281 759 1,122 (32 %) TEPEZZA ® 520 56 576...
Keep reading with a free account
The rest of this article, and every signal for Amgen, is in your free account.
Extracted from this sentence
Total product sales $ 6,990 $ 2,547 $ 9,537 $ 8,771 9 %
